目的观察小剂量地塞米松联合优思弗治疗慢性乙型肝炎肝内胆汁淤积的临床疗效。方法选取68例慢性乙型肝炎伴肝内胆汁淤积患者,随机分为治疗组38例和对照组30例,其中治疗组在综合治疗的基础上应用小剂量地塞米松联合优思弗,对照组采用S-腺苷蛋氨酸及常规综合治疗,疗程4周。观察两组治疗前后丙氨酸氨基转移酶(ALT)、总胆红素(TBIL)、直接胆红素(DBIL)、γ-谷氨酰转肽酶(GGT)、碱性磷酸酶(AKP)等指标。结果治疗后TBIL、DBIL、AKP、GGT四项指标治疗组显著低于对照组,差异均有显著统计学意义(P<0.01),治疗组的显效率显著高于对照组(P<0.05),而两组总有效率差异无统计学意义(P>0.05)。结论在常规保肝抗病毒治疗的基础上应用小剂量地塞米松联合优思弗治疗慢性乙型肝炎肝内胆汁淤积疗效显著,安全性良好。 Objective To observe the clinical effect of low-dose dexamethasone combined with Ursofora on intrahepatic cholestasis of chronic hepatitis B patients. Methods Sixty-eight patients with chronic hepatitis B and intrahepatic cholestasis were randomly divided into treatment group (n = 38) and control group (n = 30). The treatment group was treated with low dose dexamethasone combined with eptifibatide and the control group S-adenosyl methionine and conventional treatment, the course of 4 weeks. The levels of ALT, TBIL, DBIL, GGT and AKP in the two groups were observed before and after treatment. And other indicators. Results After treatment, the four indexes of TBIL, DBIL, AKP and GGT in the treatment group were significantly lower than those in the control group (P <0.01), and the effective rate in the treatment group was significantly higher than that in the control group (P <0.05) The total effective rate was no significant difference between the two groups (P> 0.05). Conclusion The treatment of chronic hepatitis B with intrahepatic cholestasis based on routine hepatoprotective anti-virus therapy based on the application of low-dose dexamethasone combined with Uspres has significant effect and good safety.